These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 2316280)
1. Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2. Flexner C; Moss B; London WT; Murphy BR Vaccine; 1990 Feb; 8(1):17-21. PubMed ID: 2316280 [TBL] [Abstract][Full Text] [Related]
2. Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression. Flexner C; Hügin A; Moss B Nature; 1987 Nov 19-25; 330(6145):259-62. PubMed ID: 3118219 [TBL] [Abstract][Full Text] [Related]
3. Response of monkeys to vaccination with recombinant vaccinia virus which coexpress HIV gp160 and human interleukin-2. Ruby J; Brinkman C; Jones S; Ramshaw I Immunol Cell Biol; 1990 Apr; 68 ( Pt 2)():113-7. PubMed ID: 2200748 [TBL] [Abstract][Full Text] [Related]
4. Evaluation in non-human primates of the safety, immunogenicity and efficacy of recombinant vaccinia viruses expressing the F or G glycoprotein of respiratory syncytial virus. Olmsted RA; Buller RM; Collins PL; London WT; Beeler JA; Prince GA; Chanock RM; Murphy BR Vaccine; 1988 Dec; 6(6):519-24. PubMed ID: 3072795 [TBL] [Abstract][Full Text] [Related]
5. The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys. Durbin AP; Wyatt LS; Siew J; Moss B; Murphy BR Vaccine; 1998 Aug; 16(13):1324-30. PubMed ID: 9682397 [TBL] [Abstract][Full Text] [Related]
6. Humoral immune response elicited by highly attenuated variants of vaccinia virus and by an attenuated recombinant expressing HIV-1 envelope protein. Dallo S; Maa JS; Rodriguez JR; Rodriguez D; Esteban M Virology; 1989 Nov; 173(1):323-9. PubMed ID: 2510402 [TBL] [Abstract][Full Text] [Related]
7. Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. Ramírez JC; Gherardi MM; Rodríguez D; Esteban M J Virol; 2000 Aug; 74(16):7651-5. PubMed ID: 10906221 [TBL] [Abstract][Full Text] [Related]
8. Secondary vaccination with vaccinia virus recombinants: role of residual virulence of recombinants and immunogenicity of extrinsic antigens. Kutinová L; Ludvíková V; Nemecková S; Hainz P; Simonová V; Vonka V Vaccine; 1999 Mar; 17(9-10):1186-92. PubMed ID: 10195631 [TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of recombinants based on the genetically-engineered vaccinia strain, NYVAC. Tartaglia J; Cox WI; Pincus S; Paoletti E Dev Biol Stand; 1994; 82():125-9. PubMed ID: 7958466 [TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate. Kantor J; Irvine K; Abrams S; Snoy P; Olsen R; Greiner J; Kaufman H; Eggensperger D; Schlom J Cancer Res; 1992 Dec; 52(24):6917-25. PubMed ID: 1458480 [TBL] [Abstract][Full Text] [Related]
11. Immunization with vaccinia virus recombinants that express the surface glycoproteins of human parainfluenza virus type 3 (PIV3) protects patas monkeys against PIV3 infection. Spriggs MK; Collins PL; Tierney E; London WT; Murphy BR J Virol; 1988 Apr; 62(4):1293-6. PubMed ID: 2831389 [TBL] [Abstract][Full Text] [Related]
12. Influence of the parental virus strain on the virulence and immunogenicity of recombinant vaccinia viruses expressing HBV preS2-S protein or VZV glycoprotein I. Kutinová L; Ludvíková V; Krystofová J; Otavová M; Simonová V; Nĕmecková S; Hainz P; Vonka V Vaccine; 1996 Aug; 14(11):1045-52. PubMed ID: 8879101 [TBL] [Abstract][Full Text] [Related]
13. Effect of virulence on immunogenicity of single and double vaccinia virus recombinants expressing differently immunogenic antigens: antibody-response inhibition induced by immunization with a mixture of recombinants differing in virulence. Kutinová L; Ludvíková V; Marešová L; Němečková Š; Brouček J; Hainz P; Vonka V J Gen Virol; 1999 Nov; 80 ( Pt 11)():2901-2908. PubMed ID: 10580051 [TBL] [Abstract][Full Text] [Related]
14. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma. Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252 [TBL] [Abstract][Full Text] [Related]
15. Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection. Ramshaw IA; Andrew ME; Phillips SM; Boyle DB; Coupar BE Nature; 1987 Oct 8-14; 329(6139):545-6. PubMed ID: 3498904 [TBL] [Abstract][Full Text] [Related]
16. Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus. Collins PL; Purcell RH; London WT; Lawrence LA; Chanock RM; Murphy BR Vaccine; 1990 Apr; 8(2):164-8. PubMed ID: 2336876 [TBL] [Abstract][Full Text] [Related]
17. Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells. Bennink JR; Yewdell JW; Smith GL; Moller C; Moss B Nature; 1984 Oct 11-17; 311(5986):578-9. PubMed ID: 6332992 [TBL] [Abstract][Full Text] [Related]
18. Roles of vaccinia virus in the development of new vaccines. Moss B; Fuerst TR; Flexner C; Hugin A Vaccine; 1988 Apr; 6(2):161-3. PubMed ID: 3291453 [TBL] [Abstract][Full Text] [Related]
19. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Buller RM; Smith GL; Cremer K; Notkins AL; Moss B Nature; 1985 Oct 31-Nov 6; 317(6040):813-5. PubMed ID: 4058585 [TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and virulence of attenuated vaccinia virus Tian Tan encoding HIV-1 muti-epitope genes, p24 and cholera toxin B subunit in mice. Du S; Wang Y; Liu C; Wang M; Zhu Y; Tan P; Ren D; Li X; Tian M; Yin R; Li C; Jin N J Virol Methods; 2015 Jul; 219():1-9. PubMed ID: 25796990 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]